Cue Biopharma

$3.23 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About Cue Biopharma

Cue Biopharma Inc is a development-stage immunotherapy company. The Company is focused at developing biologics engineered to selectively modulate disease-relevant T cell subsets to treat cancer and autoimmune disease. Its Immuno-Oncology pipeline includes CUE-100 Framework, and CUE-200 Framework; and autoimmune pipeline includes MHC Class I Program, and MHC Class II Program. The CUE-100 Framework restricts the activity of T cell populations. The CUE-200 Framework enables potent, long-lived anti-tumor T cell responses. The Autoimmune disease therapy protects the healthy cells from immune attack.

Stock Analysis

last close $2.82
1-mo return -1.4%
3-mo return -29.7%
avg daily vol. 170.04T
52-week high 18.42
52-week low 2.36
market cap. $108M
forward pe -
annual div. -
roe -68.3%
ltg forecast -
dividend yield -
annual rev. $14M
inst own. 51.5%
baraka

Subscribe now for daily local and international financial news

Subscribe